What Investors Can Learn From Biogen's Drug Approval That No One Wants
In 2021, Biogen (NASDAQ: BIIB) received approval from the U.S. Food and Drug Administration (FDA) for its Alzheimer's drug candidate, Aduhelm. The approval was controversial, as some argued Biogen's clinical trials failed to prove the treatment's efficacy.
In this video clip from "The Pharma & Biotech Show," recorded on Feb. 9, Motley Fool contributor Taylor Carmichael asks Dr. Frank David, author of The Pharmagellan Guide to Analyzing Biotech Clinical Trials, about what Biogen's drug approval means for investors and other biopharma companies.
Source Fool.com
